A Study of IBI362 in Participants With Type 2 Diabetes

NCT05606913 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the medication IBI362 in adults with type 2 diabetes to see how it impacts blood sugar levels over 28 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 731 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-01 · est. completion 2024-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05606913 ↗

Description as written by the study sponsor.

This trial is conducted in China. The aim of the trial is to evaluate efficacy and Safety of IBI362 Versus dulaglutide as add-on to Metformin and/or SGLT2 inhibitor or TZD in Subjects With Type 2 Diabetes.

Treatments tested

dulaglutide Drug

Dulaglutide administered subcutaneously (SC) once a week.
IBI362 Drug

IBI362 administered subcutaneously (SC) once a week.

Main thing measured	HbA1c change from baseline at week 28
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05606913 ↗